7210 Wareham Drive, Tampa, FL 33647
March 17, 2026 Weight Watchers reports its 2025 results yesterday. The firm’s revenues came in at $710 million, a 9.6% decline from 2024 revenues of $786 million. The company is expecting an 11% decrease in 2026 revenues, to between $620 and $635 million. 2025 Total Revenue and Adjusted EBITDA above high end of previously provided […]
Weight Watchers Reports Q4 & Full Year 2025 Results, 2026 Guidance Read More »
March 15, 2026 Medifast is an MLM (multilevel marketer) that sells meal replacements and diet foods, via health coaches. Their sales declined by 36% in 2025, to $386 million. Herbalife is another MLM that sells meal replacements and appetite suppressants, via health coaches. Their weight loss product sales in North America only declined by an
A Tale of Two MLM Competitors Read More »
March 12, 2026 The FDA is finally cracking down on telehealth companies marketing compounded weight loss drugs, warning them not to imply their products are FDA-approved or that they manufacture the medications. Roughly 30% of the more than 70 telehealth companies warned in the past six months rely on just four nationwide “white-label” medical groups
FDA Cracks Down on Telehealth Companies Read More »
Jan. 6, 2026 Novo Nordisk launched the pill version of its popular obesity medication Wegovy on Monday Jan. 5. The firm aimed to capture patients with a cash-pay discount — $149 a month for the lowest starting doses of the medication through April 15. It’s also trying to onboard new patients through a growing number
Telehealth Companies Offer Novo’s Wegovy pill Read More »
Dec. 22, 2025 The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy, the first daily oral medication for obesity treatment. The once-daily tablet — called the Wegovy pill — is the “first and only” oral GLP-1 medicine, or glucagon-like peptide-1, receptor agonists, according to Novo
FDA Approves Novo’s Wegovy Weight Loss Pill Read More »
Nov. 17, 2025 Due to increased competition in the weight loss market and intense pressure from President Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and diabetes drugs for cash-paying patients. This is is the latest step in the firm’s efforts to provide discounts to Americans willing to buy
Novo Nordisk Lowers Weight Loss Drug Prices Read More »
Nov. 6, 2025 Weight loss products are a major part of Herbalife’s business, accounting for 55% of total sales for the first nine months of 2025. According to Stephan Gratziani, CEO,… “Herbalife’s third-quarter performance reflects continued progress in our transformation strategy, as well as disciplined financial and operational execution. With North America returning to growth
Herbalife Reports 3rd Qtr. Results Read More »
Nov. 6, 2025 According to WW management: “WeightWatchers is entering a new era, uniquely positioned at the intersection of medical innovation and behavioral science, to lead this rapidly evolving weight health market,” said Tara Comonte, CEO of WeightWatchers. “GLP-1s are a breakthrough in obesity care, but real success, with or without medication, comes from combining
Weight Watchers Reports 3rd Qtr. Results Read More »
Nov. 4, 2025 Management reported the foillowing: Revenue: $89.4 million, with revenue per active earning coach of $4,585 Active Coaches: Independent active earning OPTA VIA ® coaches of 19,500 Net Loss: $2.3 million or $0.21 loss per diluted share Strong Balance Sheet: $173.5 million in cash, cash equivalents, and investment securities with no debt “We’re transforming Medifast from a
Medifast Reports Q3 Results – Slide Continues Read More »
Oct. 31, 2025 Zach Yadegari is the 18-year old co-founder and CEO of Cal AI, a calorie-tracking mobile app he launched from his parents’ home in Roslyn, New York, in May 2024. It has amassed 8.3 million downloads so far and growing. The company says that it nets $1.4 million per month profit, after expenses,
Sucess Story – Cal AI Weight Loss App Read More »